"Felix receives a significant stake from Advent"
In a strategic move to expand its portfolio in the global animal pharmaceuticals industry, leading private equity firm Advent International has announced the acquisition of a significant minority stake in Felix Pharmaceuticals Pvt Ltd.
The legal advisors for this transaction were not explicitly mentioned in the search results regarding this specific transaction. However, Advent International is known to work with various legal firms, and for other transactions, they have partnered with firms like Weil, Gotshal & Manges LLP. For the Felix transaction, the tax advisors were David Kilty and Nicola Cavey from Arthur Cox.
The advisory team for Advent International was led by Michael Coyle and included a diverse group of professionals from different departments. Colin Kavanagh was part of the Life Sciences department, while Simon Breen and Robert Byrne were part of the Competition and Regulated Markets department. David Kilty and Nicola Cavey were part of the Tax department. The team also included Tim Gleeson, Daire Cassidy, Glyn McCormack, and Sondos Si*d*diqi.
Felix Pharmaceuticals Pvt Ltd is a leading player in the global Gx animal pharma sector. The acquisition is expected to strengthen Advent International's position in the animal health market and support the growth of Felix Pharmaceuticals.
For more information about Advent International and their latest investments, please visit their website.
Advent International, a prominent private equity firm in finance, is strengthening its position in the animal health market by acquiring a stake in Felix Pharmaceuticals Pvt Ltd, a leading player in the global Gx animal pharma sector. The transaction's tax advisors were David Kilty and Nicola Cavey from Arthur Cox, indicating a connection between finance and private equity in this deal.
